June is Men's Health Month. Other than skin cancer, prostate cancer is the most common type of cancer in American men. It's the second-leading cause of cancer death in American men, behind only lung cancer.
Jun 15, 2022
0
15
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than ...
Jun 2, 2022
0
1
Researchers at the Abramson Cancer Center at the University of Pennsylvania have found a way to identify lung cancer at the cellular level in real time during a biopsy, offering promise in the ability to detect the disease ...
May 18, 2022
0
45
UC Davis Health physicians have performed the first single-anesthesia diagnosis to treatment of lung cancer using a fully robotic approach in the UC Health System.
May 17, 2022
0
11
Analyzing cancer DNA in spinal fluid could speed up and improve the diagnosis of breast cancer which has spread to the brain and spinal cord, according to a new pilot study.
Mar 21, 2022
0
21
Patients who are at a higher risk of their lung cancer returning can be identified by a personalized blood test that is performed after treatment, according to researchers at the University of Cambridge.
Mar 18, 2022
0
72
For the first time, the high safety and low mortality of a still novel, simpler procedure for lung biopsies has also been shown in a European context. The so-called transbronchial cryobiopsy was performed in 75 patients in ...
Mar 4, 2022
0
21
To diagnose lung cancer, tumor tissue is collected from a patient and checked for signs of cancer. However, this is not always possible due to tumor location, and can be painful for the patient. For his Ph.D. research, Remco ...
Dec 14, 2021
0
1
A pilot study comparing the effects of a liquid biopsy with tissue-based test showed that liquid biopsy turn-around time for results was approximately 10 days faster than the tissue biopsy, according to research presented ...
Oct 2, 2020
0
14
Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower ...
Feb 26, 2020
0
2
